{"id":"dexmedetomidine-0-25-g-kg-iv","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Hypotension"},{"rate":"10-25","effect":"Bradycardia"},{"rate":"5-15","effect":"Hypertension (transient, initial)"},{"rate":"5-10","effect":"Dry mouth"},{"rate":"5-10","effect":"Rebound hypertension on discontinuation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug is commonly used for procedural sedation and ICU sedation in mechanically ventilated patients.","oneSentence":"Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:30.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sedation of initially intubated and mechanically ventilated patients in intensive care settings"},{"name":"Procedural sedation in awake patients undergoing diagnostic or therapeutic procedures"}]},"trialDetails":[{"nctId":"NCT07231926","phase":"NA","title":"Intrathecal Morphine for Recovery and Outcomes After VATS","status":"RECRUITING","sponsor":"Ataturk University","startDate":"2025-12-01","conditions":"Postoperative Pain Management in Video-Assisted Thoracoscopic Surgery","enrollment":52},{"nctId":"NCT07190612","phase":"PHASE4","title":"Efficacy of Propofol Combination With Either Ketamine, Dexmedetomidine or Midazolam for Sedation During Upper Gastrointestinal Endoscopic Procedures","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2025-12","conditions":"Upper Gastrointestinal Endoscopy, Anesthesia","enrollment":75},{"nctId":"NCT04751812","phase":"NA","title":"Venous Cannulation Pain to Guide Choice of Anesthetic Method","status":"COMPLETED","sponsor":"Region Halland","startDate":"2022-03-01","conditions":"Pain, Postoperative, Pain Prediction, Laparoscopic Surgery","enrollment":270},{"nctId":"NCT06743919","phase":"PHASE4","title":"Adding Magnesium Sulfate or Dexmedetomidine to Bupivacaine in Oblique Subcostal Tap Block for Laparoscopic Cholecystectomy: a Randomized Double -Blind Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-01-01","conditions":"Laparoscopic Cholecystectomy","enrollment":63},{"nctId":"NCT06685081","phase":"NA","title":"Dexmedetomidine for Improved Pain Relief and Recovery in Spine Surgery","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2024-07-01","conditions":"Pain, Postoperative","enrollment":150},{"nctId":"NCT05386095","phase":"NA","title":"Axillary Brachial Plexus Block Using 0.25% Bupivacaine Versus Using 0.19%Bupivacaine in Pediatrics","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-05-29","conditions":"Acute Postoperative Pain, Motor Activity","enrollment":60},{"nctId":"NCT02141412","phase":"PHASE4","title":"Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2009-09","conditions":"Anesthesia Recovery, Anesthesia Emergence, Shivering","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"dexmedetomidine 0.25 µg/kg IV","genericName":"dexmedetomidine 0.25 µg/kg IV","companyName":"American University of Beirut Medical Center","companyId":"american-university-of-beirut-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of initially intubated and mechanically ventilated patients in intensive care settings, Procedural sedation in awake patients undergoing diagnostic or therapeutic procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}